Glenn Sblendorio - Dec 30, 2021 Form 4 Insider Report for IVERIC bio, Inc. (ISEE)

Role
CEO, Director
Signature
/s/ Todd Anderman, as Attorney-in-Fact for Glenn P. Sblendorio
Stock symbol
ISEE
Transactions as of
Dec 30, 2021
Transactions value $
-$12,673
Form type
4
Date filed
1/3/2022, 04:58 PM
Previous filing
Dec 27, 2021
Next filing
Mar 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISEE Common Stock Options Exercise $294 +100 +0.04% $2.94 279K Dec 30, 2021 Direct F1
transaction ISEE Common Stock Sale -$1.7K -100 -0.04% $17.01 279K Dec 30, 2021 Direct F1
transaction ISEE Common Stock Options Exercise $2.35K +801 +0.29% $2.94 280K Dec 31, 2021 Direct F1
transaction ISEE Common Stock Sale -$13.6K -801 -0.29% $17.01 279K Dec 31, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (Right to Buy) Options Exercise $0 -100 -0.03% $0.00 391K Dec 30, 2021 Common Stock 100 $2.94 Direct F1, F3
transaction ISEE Stock Option (Right to Buy) Options Exercise $0 -801 -0.2% $0.00 391K Dec 31, 2021 Common Stock 801 $2.94 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021.
F2 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on December 31, 2021. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F3 This option was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.